Coformulated Bictegravir/Emtricitabine/Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Assault: A Retrospective Real-World Study

被引：0
|
作者：
de Jesus, Cabrera-Lopez Teresita [1 ]
Edgar, Perez-Barragan [2 ]
Ruben, Nava-Campos Carlos [1 ]
Marla, Toiber-Rodriguez [3 ]
Carlos, Rodriguez-Aldama Juan [2 ]
Adrian, Cruz-Flores Raul [4 ]
Andrea, Gonzalez-Rodriguez [5 ]
机构：
[1] Clin Especializada Condesa Iztapalapa, Dept Gynecol & Care Victims Sexual Assault, Mexico City, Mexico
[2] Clin Especializada Condesa Iztapalapa, Dept Infect Dis, Combate Celaya 352, Mexico City 09730, Mexico
[3] Clin Especializada Condesa Iztapalapa, Dept Mental Hlth, Mexico City, Mexico
[4] Clin Especializada Condesa Iztapalapa, Dept Epidemiol, Mexico City, Mexico
[5] Clin Especializada Condesa, Mexico City, Mexico
来源：
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 08期
关键词：
bictegravir/emtricitabine/tenofovir alafenamide; HIV; INSTI; post-exposure prophylaxis; sexual assault; HIV; HEALTH; RECOMMENDATIONS; EXPOSURE;
D O I：
10.1093/ofid/ofae436
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We report the experience of bictegravir/emtricitabine/tenofovir alafenamide for nonoccupational postexposure prophylaxis in sexual assault cases. Between June 2021 and October 2023, 39 individuals completed the 28-day follow-up; 41% experienced some side effects, and 1 person discontinued the drug because of a rash. No individuals seroconverted to HIV during the follow-up period.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Safety and Tolerability of Once Daily Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide for Postexposure Prophylaxis After Sexual Exposure
    Mayer, Kenneth H.
    Gelman, Marcy
    Holmes, Johnathon
    Kraft, Jessica
    Melbourne, Kathleen
    Mimiaga, Matthew J.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 90 (01) : 27 - 32
  • [2] Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
    Sax, Paul E.
    DeJesus, Edwin
    Crofoot, Gordon
    Ward, Douglas
    Benson, Paul
    Dretler, Robin
    Mills, Anthony
    Brinson, Cynthia
    Wei, Xuelian
    Collins, Sean E.
    Cheng, Andrew
    AIDS, 2018, 32 (12) : 1723 - 1725
  • [3] Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
    Emond, Bruno
    Rossi, Carmine
    Cote-Sergent, Aurelie
    Dunn, Keith
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Donga, Prina
    JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2021, 8 (01): : 88 - 98
  • [4] Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study
    Knobel, Hernando
    Canas-Ruano, Esperanza
    Guelar, Ana
    Knobel, Pablo
    Villar-Garcia, Judit
    Gonzalez-Mena, Alicia
    Canepa, Ceclia
    Arrieta-Aldea, Itziar
    Marcos, Augustin
    Abalat-Torrres, Agusti
    Gerri-Fernandez, Roberto
    HIV RESEARCH & CLINICAL PRACTICE, 2023, 24 (01)
  • [5] Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/Emtricitabine/Tenofovir Alafenamide
    Maggiolo, Franco
    Valenti, Daniela
    Teocchi, Rodolfo
    Comi, Laura
    Di Filippo, Elisa
    Rizzi, Marco
    JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2022, 21
  • [6] Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium
    Nasreddine, Rakan
    Florence, Eric
    Yombi, Jean Cyr
    Henrard, Sophie
    Darcis, Gilles
    Van Praet, Jens
    Vandekerckhove, Linos D.
    Allard, Sabine
    Demeester, Remy
    Messiaen, Peter
    Ausselet, Nathalie
    Delforge, Marc
    De Wit, Stephane
    HIV MEDICINE, 2023, 24 (08) : 914 - 924
  • [7] Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
    Rolle, Charlotte-Paige
    Nguyen, Vu
    Patel, Kiran
    Cruz, Dan
    DeJesus, Edwin
    Hinestrosa, Federico
    MEDICINE, 2021, 100 (38)
  • [8] Real-world efficacy of switching to bictegravir/ emtricitabine/tenofovir alafenamide in pretreated patients with triple therapy containing rilpivirine
    de Gea Grela, Alejandro
    Martin Carbonero, Luz
    Mican, Rafael
    Ignacio Bernardino, Jose
    Ramos, Luis
    Eulalia Valencia, Ma
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2022, 35 (04) : 378 - 381
  • [9] Real-world persistence with dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir-alafenamide among persons with HIV
    Martin-Zaragoza, Lorena
    Sanchez-Rubio-Ferrandez, Javier
    Onteniente-Gonzalez, Alberto
    Gomez-Bermejo, Marcos
    Rodriguez-Alvarez, Sergio Julio
    Monereo-Alonso, Alfonso
    Molina-Garcia, Teresa
    FARMACIA HOSPITALARIA, 2024, 48 (04) : T171 - T175
  • [10] A retrospective, multicentre study on the efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for the treatment of HIV in a real-world setting in Belgium
    Nasreddine, R.
    Florence, E.
    Yombi, J.
    Henrard, S.
    Darcis, G.
    Van Praet, J.
    Vandekerckhove, L.
    Allard, S.
    Demeester, R.
    Messiaen, P.
    Ausselet, N.
    Delforge, M.
    De Wit, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 116 - 117
12345